A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Acerta Pharma BV
Novartis
Massive Bio, Inc.
Incyte Corporation
BerGenBio ASA
Sumitomo Pharma America, Inc.
Celgene
Celgene
Novartis
INSYS Therapeutics Inc
Novartis